Advancing Brain Tumor Diagnosis Using Deep Learning: A Systematic and Critical Review on Methodological Approaches to Glioma Segmentation and Classification Through Multiparametric MRI

Background/Objectives: Brain tumors are highly lethal cancers, with gliomas representing the most complex subtype. Magnetic resonance imaging (MRI) is the main non-invasive imaging modality. This review evaluates deep learning (DL) and artificial intelligence methods for brain tumor segmentation and classification. Methods: In this systematic review, PubMed and Scopus were searched for articles published from 2022 to March 2025. Authors independently identified eligible studies based on predefined inclusion criteria and extracted data. The study quality and risk of bias were assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist. Results: Thirty-one studies met the inclusion criteria from 310 records, with eight addressing both segmentation and classification. Most segmentation studies used publicly available multiparametric MRI datasets. Performance varied by architecture and tumor region, with whole-tumor segmentation achieving the highest Dice Similarity Coefficient (DSC). Classical U-Nets reported DSC values ranging 80–87%, while models with residual or attention mechanisms exceeded 90%. Classification focused on tumor type and glioma grading, using features learned from multiparametric MRI. Reported accuracy ranged from 91.3% to 99.4%, with sensitivity and specificity often above 95%. However, variability across tumor subregions, limited external validation, reliance on public datasets, and heterogeneous preprocessing raise concerns about robustness and real-world generalizability. Evidence on the use of explainability methods for both tasks remains limited. Conclusions: DL models for glioma segmentation and classification demonstrate promising performance. However, standardized validation protocols, multi-center datasets, and the integration of explainable artificial intelligence techniques are needed to improve transparency, robustness, and clinical applicability.